Vijay Pandey
Overview
Explore the profile of Vijay Pandey including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
86
Citations
1155
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chen S, Zhang X, Basappa B, Zhu T, Pandey V, Lobie P
Commun Med (Lond)
. 2025 Feb;
5(1):45.
PMID: 39984660
Background: Tumor dormancy is a substantial clinical obstacle in treatment of estrogen receptor positive mammary carcinoma (ER+MC), contributing to drug resistance, metastatic outgrowth, relapse, and consequent mortality. Methods: Preclinical models...
2.
Gao J, Xu H, Zhao Y, Sun L, Zhang X, Bai Y, et al.
Nano Lett
. 2025 Feb;
25(9):3505-3514.
PMID: 39984287
Inert hexagonal boron nitride (h-BN) is a prominent two-dimensional material known for its wide bandgap, thermal stability, and biocompatibility, but it resists functionalization due to strong B-N bonds. This study...
3.
Reyad-Ul Ferdous M, Wolde T, Pandey V, Qin P
J Biomol Struct Dyn
. 2025 Feb;
:1-13.
PMID: 39936172
Obesity leads to the development of several diseases and chronic death worldwide. Mitochondrial dysfunction is one of the vital causes to develop obesity. Targeting mitochondrial uncoupling protein 1 (UCP1) may...
4.
He C, Wang X, Chiou Y, Basappa B, Zhu T, Pandey V, et al.
Cell Death Dis
. 2025 Feb;
16(1):76.
PMID: 39920140
The interaction between HER2 and ERα signaling pathways contributes to resistance to anti-estrogen and HER2-targeted therapies, presenting substantial treatment challenges in ER-positive (ER+) HER2-positive (HER2+) mammary carcinoma (MC). Trefoil Factor-3...
5.
Siddappa T, Ravish A, Xi Z, Mohan A, Girimanchanaika S, Krishnamurthy N, et al.
ACS Omega
. 2025 Jan;
10(1):114-126.
PMID: 39829533
STAT3 has emerged as a validated target in cancer, being functionally associated with breast cancer (BC) development, growth, resistance to chemotherapy, metastasis, and evasion of immune surveillance. Previously, a series...
6.
Zhang S, Tan Y, Zhang X, Basappa B, Zhu T, Pandey V, et al.
Oncogene
. 2024 Dec;
44(11):753-768.
PMID: 39658649
Intrinsic and acquired resistance represent major obstacles to optimize outcomes in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) targeted therapy in lung adenocarcinoma (LUAD). Hence, a deeper understanding...
7.
Huang P, Wolde T, Bhardwaj V, Zhang X, Pandey V
Life Sci
. 2024 Oct;
357:123113.
PMID: 39369842
Background: The immunosuppressive tumour microenvironment (TME) plays a critical role in cancer progression and relapse by significantly influencing cancer pathogenesis through autocrine and paracrine signalling. Trefoil factor 3 (TFF3), a...
8.
Wang L, Zhang X, Chen S, Ye Q, Basappa B, Zhu T, et al.
Transl Oncol
. 2024 Aug;
49:102103.
PMID: 39181117
Objective: Mitomycin C (MMC), a DNA-damaging chemotherapeutic, is commonly used clinically for recurrent cervical carcinoma (CC), either alone or in combination. MMC generates DNA damage resulting in CC cell death...
9.
Kim N, Dukanya D, Sethi G, Girimanchanaika S, Yang J, Nagaraja O, et al.
Transl Oncol
. 2024 Aug;
49:102101.
PMID: 39159553
Small molecule-driven JNK activation has been found to induce apoptosis and paraptosis in cancer cells. Herein pharmacological effects of synthetic oxazine (4aS, 7aS)-3-((4-(4‑chloro-2-fluorophenyl)piperazin-1-yl)methyl)-4-phenyl-4, 4a, 5, 6, 7, 7a-hexahydrocyclopenta[e] [1,2]oxazine (FPPO;...
10.
Yang M, Basappa B, Deveshegowda S, Ravish A, Mohan A, Nagaraja O, et al.
J Adv Res
. 2024 Jul;
PMID: 39067696
Introduction: Globally, colorectal cancer (CRC) is the third most common type of cancer, and its treatment frequently includes the utilization of drugs based on antibodies and small molecules. The development...